Higher baseline levels and serial increases in KL-6 and SP-D have been associated with greater fibrotic extent, accelerated functional decline, and poorer survival in IPF, particularly when measured during antifibrotic therapy [41]. The gene discussed is SFTPD; the disease is idiopathic pulmonary fibrosis.